NCT00512135 - Safety and Efficacy of NT 201 (IncobotulinumtoxinA [Xeomin]) in the Treatment of Glabellar Frown Lines | Biotech Hunter

Enrollment

801

Participants

Timeline

Start Date

June 18, 2007

Primary Completion Date

December 28, 2009

Study Completion Date

December 28, 2009

Conditions

Glabellar Lines

Interventions

DRUG

IncobotulinumtoxinA (Xeomin) (20 units)

Injection of a total of 20 Units incobotulinumtoxinA (Xeomin) on day one of each of up to eight cycles, reconstituted in a total injection volume of 0.5 mL administered in five equal parts of 0.1 mL to five predefined points of the glabellar area.

Trial Locations (25)

10117

Charité Berlin - Klinik für Dermatologie, Berlin

10604

Narins, White Plains

15831

Dr. Michael Sebastian, Mahlow

20146

Universität Hamburg, Hamburg

20354

SCIderm GmbH, Hamburg

27608

Flynn Consulting PLLC, Raleigh

33146

Brandt, Coral Gables

33180

Centre for Cosmetic Enhancement, Aventura

37215

Tennessee Clinical Research Center, Nashville

42275

Dr. Thomas Dirschka, Wuppertal

46032

Laser &Skin Surgery Center of Indiana, Carmel

60069

Advanced Dermatology Research Institute, Lincolnshire

60590

Johann-Wolfgang-Goethe- Universitätsklinikum Frankfurt, Frankfurt am Main

64297

Rosenparkklinik, Darmstadt

66421

Uniklinik Saarland, Homburg / Saar

68144

Schlessinger, Omaha

70006

Coleman, Metairie

80113

About Skin Dermatology, Englewood

80333

Dr. Hans-Ulrich Voigt, München

90069

Skin Care Centre, Los Angeles

02467

Skin Care Physisians of Chestnut Hill, Chestnut Hill

07042

Image Dermatology P.C., Montclair

V5Z4E1

Carruthers Dermatology Centre Inc., Vancouver

M5R3N8

Solish, Toronto

01067

Krankenhaus Dresden Friedrichstadt, Dresden